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Cisplatin is one of the most widely used and effective 
cytotoxic agents currently available for the treatment 
of soft-tissue cancers, with a reported cure rate of 
85%.[1] This antineoplastic drug inhibits tumour 
growth through the formation of DNA interstrand and 
intrastrand crosslinks, which disrupts the double-stranded DNA helical 
structure. This in turn prevents cell division and growth due to inhibition 
of DNA replication and transcription, leading directly to apoptosis.[2]
Use of cisplatin is limited by the relatively high incidence of associated 
adverse drug reactions, including neurotoxicity, ototoxicity and 
nephrotoxicity, due to the drug’s narrow therapeutic index. Cisplatin-
induced ototoxicity is characterised by high-frequency sensorineural 
bilateral hearing loss, which can be irreversible and progressive[3] and 
is often associated with tinnitus and ear pain. The hearing loss usually 
begins at high frequencies (>8 000 Hz) and may later progress to lower 
frequencies that are important for conversational speech.
According to international reports, cisplatin ototoxicity affects 
23 - 50% of adults and up to 60% of children.[4-6] However, some 
studies have reported elevated hearing thresholds in up to 100% of 
cisplatin-treated cancer patients.[1] Limited data are available on the 
incidence of drug-induced hearing impairment in Africa. The reported 
prevalence of cisplatin-induced hearing impairment and tinnitus is 
strongly dependent on the criteria and diligence of the audiological 
evaluation. The Chang ototoxicity grading scale is a modification of the 
original Brock criteria for ototoxic hearing loss.[7] Importantly, these 
criteria specify the severity of hearing loss and can be used reliably by 
audiologists, oncologists and clinical research personnel to standardise 
ototoxicity monitoring.
Drug-induced ototoxicity negatively influences an individual’s verbal-
auditory communication, resulting in a detrimental effect on learning 
and socio-emotional status.[5] Hearing loss can have educational and 
economic disadvantages including delayed speech acquisition and 
literacy and impaired cognitive skills in children, and social isolation. 
These consequences are greater in developing countries because of 
the inadequacy of rehabilitation and social service facilities. The 
development of adverse drug reactions such as ototoxicity often 
leads to discontinuation of cisplatin treatment or reduction of the 
dose. This affects compliance with treatment and ultimately leads to 
decreased survival rates in cancer patients.
Variation in susceptibility to the development of cisplatin-induced 
ototoxicity has been attributed to age at initiation of treatment, 
renal dysfunction, cumulative cisplatin dosages, cranial irradiation, 
co-administration with other ototoxic drugs, noise exposure and 
genetic factors.[8-10] The majority of studies investigating cisplatin-
induced ototoxicity have been performed on European and South 
American patient cohorts,[4-6,10] with only a single study examining 
the development of ototoxicity in Japanese head and neck cancer 
patients. The incidence rate of cisplatin-induced ototoxicity was 
reported as 77.3% in the 44 Japanese patients investigated.[11]
No clinically proven treatments for the prevention or amelioration 
of ototoxicity exist, although recent studies have highlighted the 
value of co-administration of cisplatin with otoprotectors such as 
D-methionine.[12] However, the development of ototoxicity remains the 
most significant dose-limiting factor in cisplatin-based chemotherapy 
owing to the cumulative, and often irreversible, manner in which it 
develops. Ototoxicity frequently affects the outcome of treatment, 
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yet its prevalence in cancer patients in South 
Africa (SA) is largely unreported. This 
study aimed to determine the incidence of 
cisplatin-induced ototoxicity in a population 
of patients attending Groote Schuur Hospital 
(GSH), Cape Town, SA.
Methods
Patients
A 5-year retrospective cross-sectional study 
was carried out on patients receiving high-
dose (≥60 mg/m2 per cycle) cisplatin-based 
chemotherapy with audiological monitoring 
at GSH between January 2006 and August 
2011. Ethical approval was granted by 
the Human Research Ethics Committee, 
University of Cape Town.
Socio-demographic and clinical data 
including pre-existing hearing loss, previous 
noise exposure, anatomical site of cancer 
and cumulative cisplatin dosage (mg/m2) 
were collected from patient medical records. 
Inclusion criteria were the availability of 
a baseline, and at least one additional, 
audiological assessment.
Audiometric monitoring
Assessment of hearing thresholds was 
conducted using conventional pure-tone 
audiometry in an audiometric booth using a 
GSI 61 audiometer. Air and bone conduction 
thresholds were determined at frequencies 
between 0.5 and 8 kHz. Clinical ototoxicity 
was classified according to the American 
Speech-Language-Hearing Association 
(ASHA) guidelines[13] as a 20 dB HL or greater 
hearing loss decrease in pure-tone threshold 
at any single test frequency or a 10 dB HL 
or greater hearing loss decrease at any two 
adjacent test frequencies in air conduction. 
Patients presenting with significant hearing 
loss following cisplatin treatment were further 
classified according to severity using the 
Chang ototoxicity scale.[7]
Statistical analysis
Descriptive statistics were used to analyse 
the data using the statistical environment R 
and the IBM SPSS statistics package. Kaplan-
Meier survival analysis was used to assess 
the rate of development of ototoxicity based 
on the time to hearing loss after initiation of 
cisplatin treatment. p-values of <0.05 were 
considered statistically significant.
Results
A total of 377 patients received cisplatin 
therapy during the study period. One hundred 
and seven cisplatin-receiving patients with 
comprehensive clinical and audiometric data 
were identified; however, clear cumulative 
cisplatin dosages were only available for 86 
of these patients. The study cohort consisted 
of 79 males (73.8%) and 28 females (26.2%). 
Patients were classified into two groups, based 
on the development of significant hearing loss 
following cisplatin-containing chemotherapy – 
the ototoxicity-free (no significant hearing loss) 
and ototoxicity (significant hearing loss) groups.
The ototoxicity-free group comprised 48 
patients, of whom 77.1% were male, and 
the ototoxicity group 59 patients, of whom 
71.2% were male (Table 1). The mean ages 
for the ototoxicity-free and ototoxicity groups 
were 41.6 and 44.4 years (range 14 - 72 years 
and 14 - 75 years), respectively. Gender was 
not associated with significant hearing loss 
(Fisher’s exact test, p=0.665), and there was no 
significant difference in the age distribution 
for patients who did and did not experience 
hearing loss (Wilcoxon test, p=0.910). A total 
incidence of cisplatin-induced ototoxicity of 
55.1% was observed in this SA population, 
of whom 62.7% experienced bilateral hearing 
loss. Only 3 patients in the ototoxicity cohort 
had self-reported previous noise exposure, 
and another 2 reported experiencing tinnitus 
during cisplatin treatment.
Table 1. Demographic characteristics of individuals with and without ototoxicity 
following cisplatin treatment
 
Ototoxicity free
(N=48)
Ototoxicity
(N=59) p-value
Age (years), mean (min; max) 41.6 (14; 72) 44.4 (14; 75) 0.910*
Gender (male), n (%) 37 (77.1) 42 (71.2) 0.665†
Cumulative cisplatin dose (mg/m2), median 
(min; max)
180.70
(79.11; 431.65)
236.84
(47.62; 511.56) 0.027*‡§
Ototoxicity free = patients who did not develop significant hearing loss; ototoxicity = patients who developed significant 
hearing loss.
*Wilcoxon rank-sum test.
†Fisher’s exact test.
‡Statistically significant at type 1 error rate of 5%.
§One-sided hypothesis test.
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Fig. 1. Frequency of new cisplatin-receiving patients with audiological monitoring at Groote Schuur 
Hospital. Th e frequency of these patients displays an increasing exponential trend between 2006 and 
2010. Pale blue represents patients who experienced signifi cant cisplatin-induced hearing loss and dark 
blue represents patients who did not experience hearing loss.
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Approximately half of the study participants 
(53.3%) had hearing loss before initiation of 
cisplatin-based chemotherapy, as classified 
by ASHA.[13] As expected, pre-existing 
hearing loss was significantly associated with 
age at baseline (Wilcoxon test, p<0.001), 
but it was not associated with subsequent 
cisplatin-induced hearing loss (Fisher’s exact 
test, p=0.696). The age distribution differed 
significantly according to anatomical tumour 
location (p<0.001), patients with reproductive 
cancers and osteosarcoma being younger at 
baseline audiometric analysis.
The frequency of new cisplatin-receiving 
patients per year, who were audiologically 
monitored during treatment, increased by 
300% between years 2006 and 2010, with the 
exception of 2009 (Fig. 1). It is expected that 
the frequency of cisplatin-receiving patients 
continued to increase between September 
and December 2011, since data were only 
recorded up to the end of August 2011.
The median cumulative cisplatin dosages 
were 180.70 mg/m2 and 236.84 mg/m2 for 
the ototoxicity-free and ototoxicity groups, 
respectively. Patients who received higher 
cumulative dosages during chemotherapy 
were more likely to develop significant hearing 
loss (Wilcoxon test, p=0.027) (Table 1). The 
median cumulative cisplatin dosages displayed 
an increasing trend with the severity of the 
hearing loss, although this association was 
not statistically significant (Kruskal-Wallis test, 
p=0.316) (Fig. 2).
The rate of development of hearing loss 
following cisplatin initiation was assessed using 
Kaplan-Meier survival analysis. The rate at 
which patients developed hearing loss differed 
significantly depending on the anatomical 
location of the tumour (log rank test, p=0.022). 
Patients with head and neck cancers or 
lymphoma developed hearing loss faster than 
the rest of the patients (Fig. 3). The odds 
of developing cisplatin-induced hearing loss 
were elevated for patients with head and neck 
tumours and lymphoma (logistic regression, 
odds ratio (OR) 1.824; p=0.0465 and OR 2.250; 
p=0.0563, respectively), and significantly 
reduced for patients with reproductive cancers 
(OR 0.111; p=0.0371). Notably, only 1 of the 10 
patients with reproductive cancer developed 
hearing loss. The rate of hearing loss did 
not differ significantly according to gender 
(log rank test, p=0.515), age at initiation of 
treatment (log rank test, p=0.490) or severity of 
hearing loss (log rank test, p=0.450).
Discussion
Ototoxicity has been recognised as an adverse 
effect of cisplatin treatment for almost three 
decades,[14] yet because of its high cure rate[1] 
it is administered in the first-line treatment 
of many cancer types. Furthermore, cisplatin 
has been shown to significantly increase the 
lifespan of patients,[15] and the benefit of 
chemotherapeutic treatment often outweighs 
the risk of ototoxicity. Sustaining the patient’s 
quality of life both during and after treatment 
is therefore of the utmost importance.
This is the first study that provides a 
quantitative analysis of cisplatin-induced 
ototoxicity in an adult SA population. With 
an incidence of 55.1%, this report of cisplatin-
induced hearing loss illustrates that SA adult 
patients may be at higher risk than their 
European and South American counterparts, 
for whom incidence rates of 23 - 50% have 
been reported.[4-6] We suspect that this trend 
would be similar for many other hospitals 
around SA. Since not all patients receive 
audiological monitoring during high-dose 
cisplatin treatment and this study was only 
conducted at a single major Western Cape 
hospital, our findings may under-represent 
the incidence of cisplatin-induced ototoxicity.
The increasing annual frequency of 300% 
for new cisplatin-receiving patients who were 
audiologically monitored during treatment 
between 2006 and 2010 can be attributed to 
improved awareness of the ototoxic effects 
of cisplatin on the part of SA oncologists. 
In 2009, it was reported that only half of 
SA oncologists referred patients receiving 
chemotherapy for audiological monitoring 
during treatment, even though 90% of them 
were aware that the drugs cause physical 
damage to the auditory system.[16] In this 
cohort, a minimal number (n=3) of patients 
experienced debilitating hearing loss 
(i.e. grades 3 and 4) when cisplatin was 
substituted for the less ototoxic carboplatin 
when hearing loss in the high frequencies 
was detected. This is testament to the benefits 
of the regular audiometric monitoring that 
these patients received during treatment.
Cisplatin-induced ototoxicity has been 
shown to be dependent on age at initiation of 
treatment, paediatric (<5 years) and elderly 
patients (>40 years) displaying increased 
susceptibility.[6,17] In our study, patient ages 
ranged between 14 and 75 years; however, 
there was no significant difference in the age 
distribution for patients who did and did not 
experience ototoxicity. Patient gender was 
not identified as a risk factor for cisplatin-
induced ototoxicity until recently, when 
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Fig. 2. Distribution of cumulative cisplatin dosage based on severity of hearing loss. The distribution 
displays an increasing trend with increasing severity of hearing loss experienced. The Chang ototoxicity 
grading scale was used to assess severity, with grades 1A and 1B and 2A and 2B grouped into grades 1 
and 2, respectively, owing to small sample size. Patients with grade 3 ototoxicity (n=3) are not shown.
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Yancey et al.[9] reported that male paediatric 
patients were four times more likely to 
experience ototoxicity than females. We 
found no association between gender and 
the development of significant hearing loss.
Cumulative dosages of cisplatin have been 
identified as the most important predictor 
of cisplatin-induced ototoxicity, particularly 
cumulative doses above 400 mg/m2.[6,9,10] In a 
recent study investigating a cohort of Japanese 
head and neck cancer patients, the threshold 
cumulative dosage of cisplatin was 200 mg/m2, 
above which average hearing thresholds were 
significantly reduced in these patients.[11] 
Our data indicate that SA patients who 
received higher cumulative cisplatin dosages 
during chemotherapy were more likely to 
develop significant hearing loss, with median 
cumulative dosages of 180.70 mg/m2 and 
236.84 mg/m2 for the ototoxicity-free and 
ototoxicity groups, respectively. Our findings 
therefore suggest that cumulative cisplatin 
dosage may be the most important predictor 
of ototoxcity in this population.
The risk of developing cisplatin-induced 
hearing loss was significantly reduced in 
patients with reproductive cancers. These 
patients receive each cycle of cisplatin 
treatment intravenously over a period of 
3 - 5 days, which may account for the 
low incidence of ototoxicity in this group. 
The odds of developing cisplatin-induced 
hearing loss were elevated in head and 
neck cancer and lymphoma patients, and 
hearing loss occurred at a faster rate than 
in the rest of the patients investigated. 
Treatment for head and neck carcinomas 
and lymphomas usually involves surgery, 
chemotherapy and cranial irradiation, 
either singly or in combination. Although 
cranial irradiation was not investigated in 
this cohort, it has been identified as a risk 
factor for the development of ototoxicity. [18,19] 
We hypothesise that the high incidence 
of hearing loss in these groups may be 
attributed to the use of cranial irradiation 
during treatment. 
Other previously identified risk factors 
for cisplatin-induced ototoxicity, including 
previous exposure to ototoxic agents such 
as the aminoglycoside antibiotics and 
tuberculosis treatment, were not recorded. 
Previous noise exposure and renal 
dysfunction[18,19] were not investigated in this 
study owing to lack of clinical data.
The consequences of hearing loss can be 
debilitating and may limit the contribution 
of sufferers to society, adding to the 
economic burden on SA. Our data highlight 
the importance of regular audiological 
monitoring of patients receiving high-dose 
cisplatin treatment. Adequate knowledge of 
the complication of ototoxicity on the part 
of clinicians may facilitate the prevention 
or amelioration of further ototoxic damage 
through administration of otoprotective 
agents, or a change of chemotherapeutic drugs. 
Further research should aim to understand 
other risk factors, particularly genetic 
predictors of cisplatin-induced ototoxicity in 
the uniquely diverse SA population.
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Fig. 3. Kaplan-Meier estimates of cisplatin-induced hearing loss-free survival based on anatomical site 
of cancer. Head/neck cancer and lymphoma patients developed hearing loss at a faster rate than the 
other cancer groups investigated.
